Although the administration of OPN acutely is neuroprotective (Meller et al., 2005; Doyle et al., 2008), these data suggest that reducing OPN activity in the chronic inflammatory process may be a target for therapeutic intervention in recovering stroke patients. Here, SPP1 is linked to stroke disorder.